Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
| ▸ | HMGCR | P04035 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11960338 | 0.83 | CYP3A4 (0.33) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL12340827 | 0.81 | CA2 (0.50) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL20122652 | 0.80 | HMGCR (0.34) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL17816268 | 0.79 | — | — | |
| SCHEMBL18699160 | 0.79 | CYP3A4 (0.31) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL786348 | 0.78 | NOS3 (0.36) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL278866 | 0.78 | CA2 (0.37) | — | |
| SCHEMBL22856616 | 0.77 | HMGCR (0.30) | HMGCR | |
| SCHEMBL19191786 | 0.73 | PIK3CD (0.31) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL15859025 | 0.73 | HPGD (0.33) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| EP-4328230-A2 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20230348478-A1 | TYK2 PSEUDOKINASE LIGANDS | VENTYX BIOSCIENCES, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11753411-B2 | Substituted pyrazolo[1,5-a]pyrimidines as TYK2 pseudokinase ligands | VENTYX BIOSCIENCES, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230271960-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS INC (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230257352-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-08-17 | — | — | US | disclosed |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| US-20230181546-A1 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | PLIANT THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230181546-A1 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | PLIANT THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20130225619-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130131064-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-23 | — | — | US | disclosed |
| US-8309577-B2 | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120252830-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | NOVARTIS AG (CH) | 2012-10-04 | — | — | US | disclosed |
| US-20120035178-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-09 | — | — | US | disclosed |
| US-20120035189-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-09 | — | — | US | disclosed |
| US-7863291-B2 | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-22 | — | — | US | disclosed |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-29 | — | — | US | disclosed |
| US-7384552-B2 | Proton-conducting membrane and the use thereof | BASF FUEL CELL GMBH (DE) | 2008-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | CYP3A4 2815/4885CYP2D6 1921/4885TSHR 372/4885 |
| US-11753411-B2 | Substituted pyrazolo[1,5-a]pyrimidines as TYK2 pseudokinase ligands | TYK2, JAK1, JAK2 | CYP3A4 2825/4885CYP2D6 1865/4885TSHR 418/4885 |
| US-20120035189-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | CYP3A4 2815/4885CYP2D6 1921/4885TSHR 372/4885 |
| US-20230271960-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | CYP3A4 4362/4885CYP2D6 3537/4885TSHR 3026/4885 |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | CYP3A4 1831/4885CYP2D6 625/4885TSHR 1194/4885 |
| US-20120035178-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | CYP3A4 2815/4885CYP2D6 1921/4885TSHR 372/4885 |
| US-20120252830-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | MME, GABRB1, GABRE | CYP3A4 1933/4885CYP2D6 1432/4885TSHR 1971/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | CYP3A4 4464/4885CYP2D6 4827/4885TSHR 3456/4885 |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | CYP3A4 2815/4885CYP2D6 1921/4885TSHR 372/4885 |
| US-20230348478-A1 | TYK2 PSEUDOKINASE LIGANDS | TYK2, JAK2, PTK2B | CYP3A4 4276/4885CYP2D6 4203/4885TSHR 672/4885 |
| US-20230257352-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | CYP3A4 4349/4885CYP2D6 4304/4885TSHR 2839/4885 |
| US-20130131064-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | CYP3A4 2815/4885CYP2D6 1921/4885TSHR 372/4885 |
| US-20130225619-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR DISEASE TREATMENT | CLN6, ALDH1A2, PDE6D | CYP3A4 4047/4885CYP2D6 3441/4885TSHR 2420/4885 |
| US-20230181546-A1 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | ITGA5, ITGAL, ITGB5 | CYP3A4 4075/4885CYP2D6 3872/4885TSHR 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.